Horng Chen

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide
    Horng H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 60:2305-12. 2012
  2. ncbi Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure
    H H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Circulation 100:2443-8. 1999
  3. ncbi Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure
    Horng H Chen
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 53:1302-8. 2009
  4. ncbi Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure
    Horng H Chen
    Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 288:R1093-7. 2005
  5. ncbi Therapeutic potential for existing and novel forms of natriuretic peptides
    Horng H Chen
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Heart Fail Clin 2:365-73. 2006
  6. ncbi Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure
    Horng H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, MN 55905, USA
    Eur J Heart Fail 8:681-6. 2006
  7. ncbi Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study
    Horng H Chen
    Department of Internal Medicine and Division of Cardiovascular Diseases, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Circulation 116:I134-8. 2007
  8. ncbi Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure
    Horng H Chen
    Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Am Soc Nephrol 17:2742-7. 2006
  9. ncbi Pathophysiology of volume overload in acute heart failure syndromes
    Horng H Chen
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Am J Med 119:S11-6. 2006
  10. ncbi Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study
    H H Chen
    Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN 55904, USA
    Heart 95:1315-9. 2009

Research Grants

  1. Human Cardiorenal Syndrome
    Horng Chen; Fiscal Year: 2009
  2. Human Cardiorenal Syndrome
    Horng H Chen; Fiscal Year: 2010

Collaborators

Detail Information

Publications53

  1. ncbi Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide
    Horng H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 60:2305-12. 2012
    ..The purpose of the present study was to translate our laboratory investigations to establish safety and efficacy of 8 weeks of chronic SC B-type natriuretic peptide (BNP) administration in human Stage C heart failure (HF)...
  2. ncbi Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure
    H H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Circulation 100:2443-8. 1999
    ..In contrast, severe CHF is characterized by sodium retention and coactivation of both ANP and the RAAS...
  3. ncbi Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure
    Horng H Chen
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 53:1302-8. 2009
    ..The purpose of this study was to test the hypothesis that local renal delivery of B-type natriuretic peptide (BNP) will overcome renal resistance to BNP without systemic hypotension...
  4. ncbi Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure
    Horng H Chen
    Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 288:R1093-7. 2005
    ..Cardiac filling pressures were reduced in all three groups. These studies also support the conclusion that in experimental overt CHF, renal resistance to natriuretic peptides in increasing rank order is BNP<Uro<ANP...
  5. ncbi Therapeutic potential for existing and novel forms of natriuretic peptides
    Horng H Chen
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Heart Fail Clin 2:365-73. 2006
  6. ncbi Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure
    Horng H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, MN 55905, USA
    Eur J Heart Fail 8:681-6. 2006
    ..However, it is unknown if this will lead to the development of tolerance to exogenous BNP...
  7. ncbi Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study
    Horng H Chen
    Department of Internal Medicine and Division of Cardiovascular Diseases, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Circulation 116:I134-8. 2007
    ..B-type natriuretic peptide is a cardiac hormone that enhances glomerular filtration rate and inhibits aldosterone. Cystatin has been shown to be a better endogenous marker of renal function than creatinine...
  8. ncbi Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure
    Horng H Chen
    Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Am Soc Nephrol 17:2742-7. 2006
    ....
  9. ncbi Pathophysiology of volume overload in acute heart failure syndromes
    Horng H Chen
    Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Am J Med 119:S11-6. 2006
    ..Future approaches to HF treatment should focus on the more accurate assessment and management of volume status in an effort to improve patient care...
  10. ncbi Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study
    H H Chen
    Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN 55904, USA
    Heart 95:1315-9. 2009
    ....
  11. ncbi Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure
    H H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Hypertension 38:187-91. 2001
    ....
  12. ncbi The modulating actions of sulfonylurea on atrial natriuretic peptide release in experimental acute heart failure
    H H Chen
    Cardiorenal and Cardiovascular Research Laboratories, Division of Cardiovascular Diseases, Departments of Medicine, Physiology and Pharmacology, Mayo Clinic, Mayo Foundation, Rochester, MN 55905, USA
    Eur J Heart Fail 2:33-40. 2000
    ..This study defined the modulating actions of sulfonylurea on acute release of atrial natriuretic peptide (ANP) in experimental acute heart failure...
  13. ncbi Natriuretic peptides in the pathophysiology of congestive heart failure
    H H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Guggenheim 9, 200 First Street SW, Rochester, MN 55905, USA
    Curr Cardiol Rep 2:198-205. 2000
    ..Recently, a fourth member of the natriuretic peptide, Dendroaspis natriuretic peptide (DNP) has been reported to be present in human plasma and atrial myocardium and is elevated in plasma of human CHF...
  14. ncbi Subcutaneous administration of brain natriuretic peptide in experimental heart failure
    H H Chen
    Department of Physiology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 36:1706-12. 2000
    ....
  15. ncbi Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide
    Horng H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Am Coll Cardiol 40:1186-91. 2002
    ....
  16. ncbi Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure
    Horng H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Physiol Renal Physiol 284:F1115-9. 2003
    ..These findings support the use of AT(1) receptor blockade for human CHF requiring acute diuretics to improve renal hemodynamic and tubular function and to suppress aldosterone...
  17. ncbi Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition
    Horng H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Circulation 105:999-1003. 2002
    ..1 (NEP) and ACE. We hypothesized that acute VPI administration would potentiate the cardiorenal actions of SQ BNP in experimental CHF...
  18. ncbi The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction
    Theophilus E Owan
    Mayo Clinic College of Medicine, Division of Cardiovascular Diseases, Rochester, Minneosta 55905
    J Card Fail 14:267-75. 2008
    ..We hypothesized that brain natriuretic peptide (nesiritide) added to standard HF therapy would preserve renal function and enhance diuretic responsiveness...
  19. ncbi Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators
    Fernando L Martin
    Division of Cardiovascular Diseases, Cardiorenal Research Laboratory, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Rev Cardiovasc Med 9:39-45. 2008
    ..Vasodilators, especially those that are linked to cGMP activation, may provide an alternative approach...
  20. ncbi Renal and humoral pathophysiological actions of angiotensin II in congestive heart failure
    Zaur Mirzoyev
    Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    Drugs Today (Barc) 41:129-39. 2005
    ..In addition, we will also review the different therapeutic approaches that interrupt the RAAS and the evidence that supports their utility in congestive heart failure (CHF)...
  21. ncbi The FDA and the new biology
    Robert D Simari
    Division of Cardiovascular Diseases, Heart and Lung Research Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Cardiovasc Transl Res 1:246-7. 2008
    ....
  22. ncbi Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure
    Fernando L Martin
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Gugg 9 01, Rochester, MN 55905, USA
    Am J Physiol Regul Integr Comp Physiol 293:R1580-5. 2007
    ..These studies have both physiological and therapeutic implications warranting further research into cardiorenal interactions in this syndrome of AHF...
  23. ncbi The role of natriuretic peptides in heart failure
    Daniel D Correa de Sa
    Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Curr Cardiol Rep 10:182-9. 2008
    ..Also, measuring natriuretic peptide levels has diagnostic and prognostic value. More studies are needed to define the full potential of this unique family of endogenous peptides...
  24. ncbi B-type natriuretic peptide: beyond a diagnostic
    Fernando L Martin
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Heart Fail Clin 4:449-54. 2008
    ....
  25. ncbi The aging heart, myocardial fibrosis, and its relationship to circulating C-type natriuretic Peptide
    S Jeson Sangaralingham
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 57:201-7. 2011
    ..Together, these studies provide new insights into myocardial aging and the relationship to the antifibrotic and antiproliferative peptide CNP...
  26. ncbi Nesiritide in acute decompensated heart failure: current status and future perspectives
    Selma F Mohammed
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
    Rev Cardiovasc Med 9:151-8. 2008
    ..An adequately powered multinational mortality trial is underway. Nesiritide represents a proven therapy for normotensive/hypertensive ADHF patients with severe symptoms at rest...
  27. ncbi Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects
    Candace Y W Lee
    Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Pharmacol 49:668-73. 2009
    ....
  28. ncbi A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension
    Paul M McKie
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
    Hypertension 56:1152-9. 2010
    ..These results suggest that M-ANP, which is more potent than ANP in normal canines, has potent blood pressure lowering and renal enhancing properties and may, therefore, serve as an ANP based therapeutic for acute hypertension...
  29. ncbi Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide
    Shuchong Pan
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Proc Natl Acad Sci U S A 106:11282-7. 2009
    ..1 enhances GFR associated with heart failure while lacking the vasoactive properties of BNP. These findings demonstrate that peptides with unique properties may be designed based on products of alternatively splicing...
  30. ncbi B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts
    Brenda K Huntley
    Cardiorenal Research Laboratory, Division of Cardiovascular Disease, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Cell Physiol 225:251-5. 2010
    ..Further, on uncoated plates, integrin alphavbeta3 blockade continued to potentiate the BNP/cGMP response. These studies suggest that both RGD containing ECM proteins and integrins may interact with BNP/NPR-A to modulate cGMP generation...
  31. ncbi Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications
    Alessandro Cataliotti
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55904, USA
    Heart Fail Clin 2:269-76. 2006
  32. ncbi Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure
    Alessandro Cataliotti
    Cardiorenal Research Laboratory, Department of Physiology and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Circulation 109:1680-5. 2004
    ..The objective of this study was to test the hypothesis that exogenous BNP enhances the renal diuretic and natriuretic actions of furosemide (Fs) and retards the activation of aldosterone in a model of CHF...
  33. ncbi Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor
    Toshihiro Tsuruda
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Circ Res 90:128-34. 2002
    ..We conclude that gp130/LIF receptor and ET(A) receptor activation are essential for cardiac fibroblast growth by CT-1 and that there is synergism with ET-1/ET(A) receptor axis...
  34. ncbi Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressure
    Alessandro Cataliotti
    Department of Physiology and Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Circulation 112:836-40. 2005
    ..We hypothesized that novel oral conjugated hBNP (CONJ-hBNP) increases plasma hBNP, activates cGMP, and reduces mean arterial pressure (MAP)...
  35. ncbi Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases
    Toshihiro Tsuruda
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Circ Res 91:1127-34. 2002
    ..These in vitro findings support a role for BNP as a regulator of myocardial structure via control of cardiac fibroblast function...
  36. ncbi Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy
    Paola Belluardo
    Cardiorenal Research Laboratory, 200 First St, SW, Rochester, MN 55905, USA
    Am J Physiol Heart Circ Physiol 291:H1529-35. 2006
    ..The later activation of both forms of BNP may be a late compensatory effect, because it correlates with severity of HTN rather than cardiac hypertrophy/remodeling...
  37. ncbi Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension
    Alessandro Cataliotti
    Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Circulation 118:1729-36. 2008
    ..We also sought to establish the ability of this new conjugate to acutely activate cGMP and to reduce blood pressure in an experimental model of angiotensin II (ANG II) -mediated hypertension...
  38. ncbi Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease
    Alessandro Cataliotti
    Cardiorenal Research Laboratory and Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Trends Cardiovasc Med 17:10-4. 2007
    ....
  39. ncbi Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure
    Alessandro Cataliotti
    Cardiorenal Research Laboratory, Department of Physiology and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Circulation 105:639-44. 2002
    ....
  40. ncbi Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention
    John A Schirger
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases and Department of Physiology, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
    Circulation 109:249-54. 2004
    ..Although acute endothelin (ET) receptor antagonism improves systemic hemodynamics in CHF, clinical trials with chronic ET receptor antagonism report worsening CHF symptoms...
  41. ncbi Regulation of circulating progenitor cells in left ventricular dysfunction
    Barry A Boilson
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn, USA
    Circ Heart Fail 3:635-42. 2010
    ..The mediators of these reductions remain undefined. To determine whether neurohumoral factors might regulate circulating CD34+ cell subsets in vivo, we studied complementary canine models of left ventricular (LV) dysfunction...
  42. ncbi Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure
    Horng H Chen
    Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Card Fail 10:115-9. 2004
    ....
  43. ncbi Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria
    Horng H Chen
    Division of Cardiovascular Diseases and the Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    J Card Fail 8:279-87. 2002
    ..CONCLUSION: This population-based study provides a comprehensive clinical profile, current management, prognosis, and predictors of outcome of patients with new onset CHF who had normal ejection fraction...
  44. ncbi Progression of preclinical diastolic dysfunction to the development of symptoms
    Daniel D Correa de Sa
    Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
    Heart 96:528-32. 2010
    ....
  45. ncbi Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation
    Delphine Detaint
    Division of Cardiovascular Diseases and Internal Medicine, Rochester, Minnesota, USA
    Am J Cardiol 97:1029-34. 2006
    ..Pronounced BNP activation is linked to a higher end-systolic volume index, for which it is a biomarker, irrespective of MR etiology and symptoms...
  46. ncbi B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome
    Delphine Detaint
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 111:2391-7. 2005
    ..Therefore, BNP activation in organic MR is an emerging biomarker of severity of MR consequences and of poor clinical outcome, and its assessment should be considered in the clinical evaluation and risk stratification of patients with MR...
  47. ncbi 76-year-old woman with chest pain
    Bryan J Krajicek
    Mayo Graduate School of Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:1435-8. 2004
  48. ncbi Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure
    Brian P Shapiro
    Department of Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:481-6. 2003
    ..We show that the BNP test can be extremely helpful when used in the correct clinical setting...
  49. ncbi Usefulness of brain natriuretic peptide levels in the clinical evaluation of patients with hypertrophic cardiomyopathy
    Josepha Binder
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Cardiol 100:712-4. 2007
    ....
  50. ncbi Exertional changes in circulating cardiac natriuretic peptides in patients with suggested coronary artery disease
    Sebastien Bergeron
    Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Am Soc Echocardiogr 19:772-6. 2006
    ..We measured plasma brain natriuretic peptide (BNP) and N-terminal atrial natriuretic peptide (ANP) levels before and after exercise stress testing and correlated results with echocardiographic evidence of ischemia...
  51. ncbi Leukemia inhibitory factor is augmented in the heart in experimental heart failure
    Michihisa Jougasaki
    Institute for Clinical Research, National Hospital Kyushu Cardiovascular Center, 8 1 Shiroyama cho, 892 0853, Kagoshima, Japan
    Eur J Heart Fail 5:137-45. 2003
    ..85, P<0.001). The present study demonstrates that cardiac LIF immunoreactivity and its gene expression are increased in a canine model of experimental CHF and suggests a potential role for LIF in the pathophysiology of CHF...
  52. ncbi Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction
    Henry G Riter
    J Am Coll Cardiol 47:2334-5. 2006
  53. ncbi Heart failure: a state of brain natriuretic peptide deficiency or resistance or both!
    Horng H Chen
    J Am Coll Cardiol 49:1089-91. 2007

Research Grants2

  1. Human Cardiorenal Syndrome
    Horng Chen; Fiscal Year: 2009
    ..This research should aid in addressing this health challenge. ..
  2. Human Cardiorenal Syndrome
    Horng H Chen; Fiscal Year: 2010
    ..This research should aid in addressing this health challenge. ..